Sun et al. [51] demonstrated that the combination therapy of PD-1 and CTLA-4 inhibitors significantly reduced the risk of tumor relapse and metastasis in mouse models, thereby markedly prolonging survival (p < 0.05). Here, CTLA4 is linked to neoplasm.